BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Innovotech Inc. (IOTp.V)'s bioFILM PA(TM) Receives Regulatory Approval In Israel


2/3/2011 3:18:48 PM

Edmonton, Alberta, February 3, 2011 – Innovotech Inc. (TSX-V: IOT), a pioneer in the field of biofilm product development, today announced that LevPharm Ltd. of Israel has received regulatory approval allowing the company to commence marketing and distributing Innovotech’s bioFILM PA™ test to hospitals possessing Cystic Fibrosis units within Israel. The marketing licence is valid for one year and will be extended subject to clinical outcomes and physician’s recommendations (regular Ministry of Health procedure).

“This is the first approval of bioFILM PA™ outside of Canada and represents an acceptance of the need for a diagnostic capable of testing organisms in a biofilm state,” said Ken Boutilier, President and CEO of Innovotech Inc. “It provides an opportunity for doctors to treat Israeli patients with effective antibiotics that are tailored to their personal chronic infections. These patients have the potential to recover more quickly, while saving the health care system money, and bacteria will have less chance to develop resistance. Biofilms are the cause of virtually all chronic bacterial infections and are notoriously hard to eradicate. Use of biofilm PA™ will result in better treatment choices right from the start."

The current market capacity in Israel for bioFILM PA™ is estimated to be over 3,000 tests per year.

bioFILM PA™ is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based Pseudomonas aeruginosa infections.

Based on Innovotech’s proprietary technology, the company is currently developing companion products to bioFILM PA™ to assist physicians in the selection of the most effective antibiotic treatment for infections caused by both gram-positive and gram-negative bacteria. In a biofilm state, these bacteria are responsible for the majority of all chronic bacterial infections.

Pseudomonas aeruginosa is a common bacterium responsible for many hospital acquired infections including ventilator-associated pneumonia and those found in patients with burns and wounds. It is also one of the major causes of lung infections in individuals with Cystic Fibrosis.

Over eighty percent of microbial infections in the body are caused by organisms in a biofilm state. Biofilm infections are known to be up to 1,000 times more resistant to antibiotics than the same organism in a free-floating state, which demonstrates why it is so critical to identify effective treatments early, such as through the bioFILM PA™ test.

About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are responsible for a host of diseases both in human health and agriculture due to their inherent resistance to existing antibiotics and disinfectants. There are currently no antibiotics, disinfectants, diagnostics or regulatory standards designed specifically for biofilm-forming organisms.

Innovotech currently has one commercial product, bioFILM PA™, and one product, Agress®, in advanced stages of development. bioFILM PA™ is the first diagnostic kit to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections and Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections.

About LevPharm Ltd.

LevPharm Ltd. is a privately owned Israeli pharmaceutical company focusing on marketing and distribution of pharmaceuticals and medical devices primarily in the area of pulmonary and CNS diseases Through their long experience in this market, the professionals at LevPharm focus on building relationships with clinicians and institutions nation-wide. LevPharm currently represents international pharmaceutical and medical device firms in Israel and is actively seeking to expand this portfolio .www. levpharm.com

For more information contact:

Amanda Stadel, Communications Officer Innovotech Inc. Phone: (780) 448-0585 ext. 224 Fax: (780) 424-0941 Email: amanda.stadel@innovotech.ca

Amanda Stadel, Communications Officer Innovotech Inc. Phone: (780) 448-0585 ext. 224 Fax: (780) 424-0941 Email: amanda.stadel@innovotech.ca

Connect with us: Website: www.innovotech.ca Blog: www.cf-test.ca Twitter:www.twitter.com/innovotech



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES